Degasperi E, et al. - From December 2014 to 2016, researchers identified features of de novo or recurrent hepatocellular carcinomas (HCCs) and factors associated with HCC development in 565 patients with cirrhosis treated with direct-acting antivirals (DAAs) at a single center in Italy. Findings revealed that HCC developed in 28 out of 505 patients without a history of HCC (de novo HCC) during a median 25 months of follow up. It was noted that the 3-year estimated cumulative probability for HCC was 6%. According to findings, most liver tumors were identified at early stages in a large, single-center cohort of consecutive patients with cirrhosis and who received DAA treatment for hepatitis C virus (HCV) infection. They suggested that male sex, diabetes, and non-invasive markers of liver fibrosis can be used to identify patients at increased risk for HCC after treatment with DAAs. They observed that diabetes was independently linked to HCC recurrence.